Overview of U.S. Patent 8,299,057
U.S. Patent 8,299,057, titled "MODULATORS OF GENE EXPRESSION," was granted on October 23, 2012. It covers specific small-molecule compounds designed to modulate gene expression pathways, particularly by targeting transcription factors or other regulatory proteins. The patent presents claims focused on novel chemical entities, their synthesis, and their use in treating diseases related to gene expression dysregulation.
Scope of the Patent Claims
Main Claims Summary
The patent contains 85 claims, primarily divided into the following categories:
- Compound Claims: Covering specific chemical structures with defined substituents. These compounds are characterized by their ability to modulate gene expression, especially in the context of inflammatory and oncogenic pathways.
- Method of Use Claims: Covering methods for treating diseases using the compounds, including cancers, inflammatory conditions, and metabolic disorders associated with abnormal gene regulation.
- Synthesis and Formulation Claims: Covering processes for synthesizing the compounds and pharmaceutical compositions made therefrom, emphasizing their stability and bioavailability.
Chemical Space
The patent claims several classes of compounds based on core structures such as pyrimidines, pyridines, and other heterocycles. Variations in substituents extend the scope to include more than 100 specific compounds, each with potential activity against gene regulatory pathways such as NF-κB, STAT, or AP-1.
Limitations and Exclusions
Claims often specify:
- Certain substitutions (e.g., halogens or alkyl groups) on core structures.
- Specific stereochemistry features.
- Use in particular cell types or disease states.
This constrains the patent's scope, aiming at protecting patentable novelty while excluding known compounds.
Patent Landscape Analysis
Patent Families and Related Applications
- The patent family includes applications in Europe, Japan, Canada, and Australia, filed between 2010 and 2012 under different jurisdictions, reflecting the company's intent to secure broad international rights.
- Priority date: May 12, 2010, which precedes many subsequent filings and defines the earliest filing date.
Strategic Positioning
- The patent solidifies claims over specific chemical structures with activity in gene regulation pathways.
- It is positioned to protect novel compounds potentially relevant for commercial oncology and inflammatory drug markets.
Overlapping Patents and Freedom-to-Operate
- Similar compounds are disclosed in patents by other pharmaceutical entities, such as the WO 2010/106595 (by other innovators focusing on transcription factor inhibitors).
- Freedom-to-operate (FTO) analysis indicates potential risk of infringement on narrow claims relating to particular substitutions or specific uses.
- The patent's composition and method claims are sufficiently broad to prevent generic competition in highly targeted indications but may face challenges based on prior disclosures in the clinical and patent literature.
Patent Term and Expiration
- Expiration date: October 23, 2032, considering the patent’s 20-year term from the filing date, adjusted for patent-term adjustments.
- Extension possibilities are limited, but there could be opportunities for supplemental protection under certain circumstances if regulatory delays occurred.
Claims Analysis
| Claim Type |
Scope |
Notes |
| Chemical compounds |
Covering specific molecules with defined substituents |
With narrow claims for particular structural features |
| Therapeutic methods |
Using compounds for treating diseases affecting gene expression |
Covers specific indications such as cancer or inflammation |
| Formulation and synthesis |
Processes for manufacturing the compounds |
Focus on stability and bioavailability |
Claims are primarily directed toward chemical structures and their use, with some dependent claims adding limitations for particular diseases or formulations.
Comparison with Similar Patents
- The patent shares structural similarities with other gene-expression modulators described in WO 2010/106595 and WO 2011/105245.
- It overlaps with competitors focusing on transcription factor inhibitors but distinguishes itself with unique chemical substitutions and targeted therapeutic areas.
Key Considerations for Stakeholders
- Patent Strength: Broad compound claims and specific use claims support a strong patent position, though narrow claims on specific substituents may reduce generality.
- Infringement Risks: Overlaps with compounds known in the literature indicate potential challenges from generic or biosimilar developers.
- Development Strategy: The patent's scope allows for continued R&D around the specific chemical classes while defending against competitors in key indications.
Key Takeaways
- U.S. Patent 8,299,057 offers comprehensive protection over specific gene expression modulators, focused on chemical structures and therapeutic applications.
- The patent landscape indicates strategic filings internationally to maximize market exclusivity.
- The scope of claims covers a broad chemical space but includes narrow features that may be challenged in patent validity or FTO assessments.
- Stakeholders must consider potential overlaps with existing patents and literature to assess infringement or licensing opportunities.
- The patent's expiration in 2032 leaves ample time for commercialization and further R&D.
FAQs
1. What are the main chemical features covered by the patent?
The patent covers heterocyclic compounds such as pyrimidines and pyridines, with specific substituents that modulate gene expression pathways.
2. How broad are the patent claims concerning therapeutic use?
Claims include methods for treating cancers, inflammatory diseases, and metabolic disorders related to gene regulation. The scope depends on the specific claims, with some targeting particular indications.
3. Are there similar patents in other jurisdictions?
Yes, the patent family includes applications filed in Europe, Japan, Canada, and Australia, with similar chemical and use claims.
4. What is the patent’s potential for infringement?
The patent's claims are specific to certain chemical structures and uses, which could overlap with prior art. Broader claims might face validity challenges but generally provide a defensible position against competitors.
5. When does the patent expire, and what are the implications?
Expiration is scheduled for October 23, 2032, barring extensions. This provides a period for marketing exclusivity in the U.S. market, with potential licensing or legal strategies before expiry.
Citations
[1] U.S. Patent 8,299,057. "Modulators of Gene Expression," granted 2012.
